目的 探討腎康注射液聯(lián)合重組人促紅素注射液治療慢性腎功能衰竭合并腎性貧血的臨床療效。方法 選取2014年5月-2016年3月在徐州市腫瘤醫(yī)院腎內(nèi)科接受治療的80例慢性腎衰竭合并腎性貧血的患者為研究對象，隨機分為對照組和治療組，每組各40例。對照組患者皮下注射重組人促紅素注射液（CHO細(xì)胞），50 IU/（kg·次^-1），2次/周，同時口服常規(guī)造血原料。治療組在對照組的基礎(chǔ)上靜脈注射腎康注射液100 mL，1次/d。兩組患者均治療3個月。觀察兩組的臨床療效，同時比較治療后1、2、3個月血常規(guī)、鐵蛋白、相關(guān)激素、腎功能指標(biāo)和藥物不良反應(yīng)。結(jié)果 治療后，對照組、治療組總有效率分別為85.0%、97.5%。兩組總有效率比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療1、2、3個月，兩組的紅細(xì)胞（RBC）、血紅蛋白（HGB）、血細(xì)胞比容（HCT）和鐵蛋白（SF）水平均較治療前升高（P<0.05）；且治療組的這些指標(biāo)優(yōu)于同期對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療1、2、3個月，兩組的電解質(zhì)鈣（Ca）水平較治療前升高，甲狀旁腺激素（PTH）、電解質(zhì)磷（P）水平較治療前降低（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于同期對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療1、2、3個月，兩組的血尿素氮（BUN）、血肌酐（Scr）、血尿酸水平均較治療前降低（P<0.05）；且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于同期對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療組患者不良反應(yīng)發(fā)生率明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 腎康注射液聯(lián)合重組人促紅細(xì)胞生成素治療慢性腎功能衰竭合并腎性貧血具有較好的臨床療效，可增強對鐵的吸收，明顯改善腎功能，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Shenkang Injection combined with recombinant human erythropoietin in treatment of chronic renal failure with renal anemia. Methods Patients (80 cases) with chronic renal failure and renal anemia in Department of Nephrology in Xuzhou Tumor Hospital from May 2014 to March 2016 were randomly divided into control group and treatment group, and each group had 40 cases. Patients in the control group were ih administered with Recombinant Human Erythropoietin Injection, 50 IU/(kg·time), twice weekly, and also were given conventional hematopoietic raw materials. Patients in the treatment group were iv administered with Shenkang Injection 100 mL on the basis of the control group, once daily. Patients in two groups were treated for 3 months. After treatment for 1, 2, and 3 months, the clinical efficacies were evaluated, andblood tests, ferritin, hormones, renal function, and adverse reaction of drug in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 85.0% and 97.5%, respectively, and there was difference between two groups (P<0.05). After treatment for 1, 2, and 3 months, levels of RBC, HGB, HCT, and SF in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment for 1, 2,and 3 months, levels of Ca in two groups were significantly increased, but levels of PTH and P in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment for 1, 2, and 3 months, levels of BUN, Scr and serum uric acid in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05).The incidence of adverse reactions in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). Conclusion Shenkang Injection combined with recombinant human erythropoietin has clinical curative effect in treatment of chronic renal failure with renal anemia, and can enhance the absorption of iron, improve renal function, which has a certain clinical application value.